Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Data Collection
Chronic Disease+11
+ Hematologic Diseases
+ Immune System Diseases
Treatment Study
Summary
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.27 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * At least 18 years old * Refractory or relapsed CLL * ECOG performance status score of 0, 1, or 2 * Each patient must sign a study-specific informed consent form Exclusion Criteria: Laboratory values of: * Platelet count \<30,000/uL * AST or ALT \>2 x the upper limit of normal (ULN) * Total bilirubin \>2 x ULN * Creatinine \>2.0 mg/dL * Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment * Women who are pregnant or lactating
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location